Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JAMES P ALLISON and SANGEETA GOSWAMI.
Connection Strength

1.124
  1. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023 04 13; 186(8):1652-1669.
    View in: PubMed
    Score: 0.222
  2. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021 04; 11(4):838-857.
    View in: PubMed
    Score: 0.193
  3. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med. 2020 06 17; 12(548).
    View in: PubMed
    Score: 0.183
  4. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
    View in: PubMed
    Score: 0.177
  5. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
    View in: PubMed
    Score: 0.160
  6. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
    View in: PubMed
    Score: 0.052
  7. Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
    View in: PubMed
    Score: 0.047
  8. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.047
  9. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.